Enfermedades gastrointestinales y hepáticas
Complejo Asistencial de Segovia
Segovia, EspañaPublicacións en colaboración con investigadores/as de Complejo Asistencial de Segovia (10)
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic
Viruses, Vol. 15, Núm. 2
-
Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
Viruses, Vol. 15, Núm. 4
2022
-
Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia
Hepatology, Vol. 76, Núm. 5, pp. 1259-1274
-
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
Medicine (United States), Vol. 101, Núm. 24, pp. E29252
-
Novel genes and sex differences in COVID-19 severity
Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806
2021
-
Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project
European Journal of Surgical Oncology, Vol. 47, Núm. 2, pp. 276-284
2020
2018
-
Risk factors for unfavourable postoperative outcome in patients with Crohn's disease undergoing right hemicolectomy or ileocaecal resection. An international audit by ESCP and S-ECCO
Colorectal Disease, Vol. 20, Núm. 3, pp. 219-227
2008
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092